Journal article
Impact of Anti-PD-1 and Anti-CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living with HIV with Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study
TA Rasmussen, L Rajdev, A Rhodes, A Dantanarayana, S Tennakoon, S Chea, T Spelman, S Lensing, R Rutishauser, S Bakkour, M Busch, JD Siliciano, RF Siliciano, MH Einstein, DP Dittmer, E Chiao, SG Deeks, C Durand, SR Lewin
Clinical Infectious Diseases | Published : 2021
DOI: 10.1093/cid/ciaa1530
Abstract
Background: Antibodies to programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) may perturb human immunodeficiency virus (HIV) persistence during antiretroviral therapy (ART) by reversing HIV latency and/or boosting HIV-specific immunity, leading to clearance of infected cells. We tested this hypothesis in a clinical trial of anti-PD-1 alone or in combination with anti-CTLA-4 in people living with HIV (PLWH) and cancer. Methods: This was a substudy of the AIDS Malignancy Consortium 095 Study. ART-suppressed PLWH with advanced malignancies were assigned to nivolumab (anti-PD-1) with or without ipilimumab (anti-CTLA-4). In samples obtained preinfusion and 1 an..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
The study was funded by the American Foundation for AIDS Research (amfAR; grant number 109226-58-RGRL to S. R. L.); the Australian National Health and Medical Research Council (NHMRC; grant number GNT1149990 to S. R. L.); the Australian Centre for HIV and Hepatitis Research (ACH2; Rasmussen 2019 to T. A. R.); and the National Institutes of Health funded Delaney AIDS Research Enterprise to find a cure (UM1AI126611) to S. R. L. The clinical trial was supported by a grant from the NCI to the AIDS Malignancy Consortium (grant number UM1 CA121947). D. P. D. was supported by public health service grants CA239583 and DE018304. C.D. was supported by the National Cancer Institute (grant number 5K23CA177321-05).